Curated News
By: NewsRamp Editorial Staff
July 06, 2026

VERAXA Biotech Advances BiTAC Platform, Eyes 2028 IND

Discuss on LinkedIn Discuss on X, formerly Twitter Discuss on Substack Discuss on Telegram participate in discussion on bluesky Participate in discussion on Mastodon View History of this news story on GitHub
Original Source

TLDR

  • VERAXA Biotech advances BiTAC platform with four T-cell engager programs, positioning for strategic partnerships and potential market advantage.
  • VERAXA prioritizes BiTAC portfolio investment while monetizing non-BiTAC assets, targeting VXA-102 IND/CTA readiness by early 2028.
  • VERAXA's next-generation cancer therapies aim to improve treatment for solid tumors, bringing hope to patients through innovative T-cell engagers.
  • VERAXA's BiTAC platform, born from EMBL breakthroughs, uses bispecific T-cell engagers to precisely target and destroy cancer cells.

Impact - Why it Matters

This news matters because VERAXA's BiTAC platform represents a novel approach to cancer immunotherapy, potentially offering more effective treatments for solid tumors. The company's progress and partner interest signal a promising future for T-cell engager therapies, which could lead to new treatment options for patients. Investors should note the company's strategic focus on monetizing non-core assets to fund development, which may enhance its financial position.

Summary

VERAXA Biotech (NASDAQ: VRXA) has released a corporate and pipeline update, detailing significant progress in the first half of 2026. The company is advancing its proprietary BiTAC(R) platform, a bispecific T-cell engager technology, and has attracted growing interest from potential pharmaceutical partners. VERAXA's pipeline now includes four BiTAC-based programs targeting solid tumors, two bispecific antibody-drug conjugate (ADC) programs, and two non-BiTAC assets available for partnering. The company plans to prioritize investment in its BiTAC portfolio while seeking to monetize selected non-BiTAC programs to finance future development, with the goal of advancing lead BiTAC-TCE candidate VXA-102 to IND/CTA readiness by early 2028.

Company executives highlighted strong industry interest in T-cell engager and ADC technologies, noting that recent partnering discussions at the BIO International Convention and other scientific meetings reinforced confidence in the BiTAC platform. VERAXA continues to refine its pipeline and partnering strategy as it develops next-generation cancer therapies. The company was founded on scientific breakthroughs at the European Molecular Biology Laboratory (EMBL) and is dedicated to building a premier engine for antibody-based therapeutics, including bispecific T cell engagers and bispecific ADCs.

For the full details, visit the original release on www.newmediawire.com. For the latest news and updates relating to VRXA, check the company’s newsroom at https://ibn.fm/VRXA. Forward-looking statements caution about risks and uncertainties.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, VERAXA Biotech Advances BiTAC Platform, Eyes 2028 IND

blockchain registration record for this content.